PCSA (Processa Pharmaceuticals) Inventory-to-Revenue: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $1.84
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Processa Pharmaceuticals's Average Total Inventories for the quarter that ended in Jun. 2026 was $0.00 Mil. Processa Pharmaceuticals's Revenue for the three months ended in Jun. 2026 was $0.00 Mil.

Processa Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2026 stayed the same from Mar. 2026 () to Mar. 2026 ()

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Processa Pharmaceuticals's Days Inventory for the three months ended in Jun. 2026 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Processa Pharmaceuticals  (NAS:PCSA) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Processa Pharmaceuticals's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0/0.000301*365 / 4
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Processa Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2026 ) / Average Total Inventories (Q: Jun. 2026 )
=0.000301 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Inventory-to-Revenue Related Terms

Processa Pharmaceuticals Inventory-to-Revenue Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Inventory-to-Revenue Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Processa Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PCSA vs EMMA, LIMN, KAPA: Inventory-to-Revenue Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals Inventory-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Inventory-to-Revenue falls into.


PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Inventory-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Processa Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Inventory-to-Revenue (A: Dec. 2025 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Processa Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue (Q: Jun. 2026 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count ) / Revenue (Q: Jun. 2026 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.84
Price